Surmodics Soars as Court Rejects Injunction Against GTCR Sale
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 11 2025
0mins
Should l Buy ?
Source: SeekingAlpha
Court Ruling on Merger: Surmodics (SRDX) shares surged 49% after a federal court denied the FTC's request to block its $627 million sale to GTCR, allowing the merger to proceed pending a temporary restraining order until November 17.
FTC's Antitrust Concerns: The FTC had filed a lawsuit in March claiming that the merger would be anticompetitive by combining the two largest manufacturers of critical medical device coatings.
Company's Position: Surmodics' CEO, Gary Maharaj, expressed optimism about the merger, stating it would benefit physicians, patients, and customers.
Details of the Deal: GTCR agreed to purchase Surmodics for $43 per share in May of the previous year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
